Why CRL Response Coordination Breaks Down
The structural problem is that CRL deficiency items require parallel workstreams across regulatory affairs, clinical, CMC, safety, and medical writing — each with its own drafting cycle and review queue. Without a unified system, ownership assignments live in email, status updates are implicit, and the CRO's view of resubmission readiness is always one meeting away from being outdated. The 14-item CRL you're holding isn't unusual in scope; what's unusual is having a process capable of managing that scope coherently across six groups simultaneously.
How an AI Agent Structures the Response Program
An AI Labor Company agent extracts coordination logic from your Vault RIM correspondence histories and prior FDA deficiency response patterns in ArisGlobal LifeSphere. In deployment, the agent parses each CRL deficiency item, assigns functional ownership, creates tracked response drafts in Confluence, and gates each item's resolution against the resubmission timeline. It integrates with Outlook for review routing and surfaces a weekly progress dashboard — by item, by functional owner, by resolution status — directly to the CRO for decision-making. Email-based coordination is replaced by a structured program with visible state.
The Business Case: Protecting the Resubmission Investment
At $2M–$8M per resubmission, the cost of a second deficiency cycle — caused by a response that misses items or lacks cross-functional coordination — is not a minor risk. The primary value here is risk avoidance: ensuring every deficiency item is addressed, owned, and resolved before submission rather than discovered during FDA review. Secondarily, compressing the time from CRL receipt to submission-ready response preserves negotiated PDUFA timelines. Teams working through this kind of deployment typically compress the uncoordinated-email phase significantly, with structured program management live in roughly ten weeks.
Can the agent handle CRLs where deficiency items span both clinical and CMC functions?
Yes. The ownership assignment logic is configured by functional domain — clinical, CMC, safety, regulatory — and items that span multiple groups are tracked with co-ownership, with the agent routing review tasks to all relevant parties.
How does the weekly dashboard reach the CRO without creating another reporting burden?
The dashboard is automatically generated from tracked item status in Confluence and delivered via Outlook on a configured cadence. The CRO receives a structured status view without any manual compilation by the regulatory affairs team.
What happens when a response draft is disputed between functional groups?
The agent flags items with unresolved disagreements and escalates them to the CRO dashboard as decision items, rather than letting conflicts sit in email threads until the last week.